Trial · NCT05166876
Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19
NCT05166876, Phase 2, Terminated, Clear Creek Bio, Inc.; results first posted 2023-02-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19. Trials, record NCT05166876. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05166876
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19
- NCT number
- NCT05166876
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 26 participants, actual
- Lead sponsor
- Clear Creek Bio, Inc.
- Conditions
- COVID-19
- Interventions
- Brequinar Sodium, Dipyridamole 75 MG, Placebo
- First posted
- 2021-12-22
- Last updated
- 2023-11-07
- Results first posted
- 2023-02-06
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and Tolerability of the Brequinar-dipyridamole Combination in COVID-19 Subjects | Day 29 | There were no subjects who experienced grade 3 and 4 toxicities and serious adverse events (SAEs) considered by the investigator to be related to the combination, brequinar alone or placebo alone. therefore frequencies of these events could not be compared. |
| Secondary | Reduction of SARS-CoV-2 Levels Using qPCR Through Day 29 and at Days 4, 8, 12, 15, 22, and 29 | Day 29 | There were no subjects with detectable viral load after baseline, therefore no analyses could be conducted regarding change in viral load from baseline of SARS-CoV-2 levels using qPCR SARS-CoV-2 levels through Day 29 and at days 4, 8, 12, 15, 22, and 29 |
| Secondary | Reduction in Time to Symptom Improvement | Day 29 | There were no subjects who had changes in symptom improvement, therefore no analyses of changes in symptom improvement could be conducted. |
| Secondary | Reduction in Percentage of Subjects Requiring Hospital Admission/Re-admission as an In-patient for >24 Hours | Day 29 | There were no subjects who required hospital admission/re-admission as an in-patient for \>24 hours, therefore no analyses could be conducted for comparative change in percentage of subjects who required hospital admission/readmission for \>24 hours. |
| Secondary | Reduction in Percentage of Subjects Requiring Medical Attended Visits, e.g., Hospitalization, Emergency Room Visits, Urgent Care/Family Doctor Visits | Day 29 | There were no subjects requiring medical attended visits, e.g., hospitalization, emergency room visits, Urgent Care/Family Doctor visits, therefore no analyses could be conducted for comparative change in percentage of subjects requiring medical attended visits, e.g., hospitalization, emergency room visits, Urgent Care/Family Doctor visits |
| Secondary | Reduction in Percentage of Subjects Requiring Supplemental Support Such as Oxygen | Day 29 | There were no subjects that required supplemental support such as oxygen, therefore analyses of comparative change in percentage of subjects requiring supplemental support such as oxygen could not be conducted. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Safety and Tolerability of the Brequinar-dipyridamole Combination in COVID-19 Subjects | Day 29 | No subjects experienced any grade 3 or 4 toxicity (related adverse event) or serious adverse event (SAE), therefore no analyses could be conducted. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Reduction of SARS-CoV-2 Levels Using qPCR Through Day 29 and at Days 4, 8, 12, 15, 22, and 29 | Day 29 | There were no subjects with detectable viral load after baseline therefore no analyses could be conducted regarding change in viral load. | ||
| SECONDARY | Reduction in Time to Symptom Improvement | Day 29 | There were no subjects with clinically significant symptoms after baseline therefore no analyses could be conducted regarding change from baseline. | ||
| SECONDARY | Reduction in Percentage of Subjects Requiring Hospital Admission/Re-admission as an In-patient for >24 Hours | Day 29 | No subjects were hospitalized in any of the groups, therefore no analyses could be conducted. | ||
| SECONDARY | Reduction in Percentage of Subjects Requiring Medical Attended Visits, e.g., Hospitalization, Emergency Room Visits, Urgent Care/Family Doctor Visits | Day 29 | No subjects required medical attended visits in any of the groups, therefore no analyses could be conducted. | ||
| SECONDARY | Reduction in Percentage of Subjects Requiring Supplemental Support Such as Oxygen | Day 29 | No subjects required oxygen in any of the groups, therefore no analyses could be conducted. |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety and Tolerability of the Brequinar-dipyridamole Combination in COVID-19 Subjects | Brequinar Monotherapy | 0 | Participants | ||
| Safety and Tolerability of the Brequinar-dipyridamole Combination in COVID-19 Subjects | Placebo | 0 | Participants | ||
| Safety and Tolerability of the Brequinar-dipyridamole Combination in COVID-19 Subjects | Brequinar-Dipyridamole Combination | 0 | Participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Brequinar Monotherapy | 7 | |
| Overall Study | STARTED | Placebo | 6 | |
| Overall Study | STARTED | Brequinar-Dipyridamole Combination | 13 | |
| Overall Study | COMPLETED | Brequinar Monotherapy | 6 | |
| Overall Study | COMPLETED | Placebo | 6 | |
| Overall Study | COMPLETED | Brequinar-Dipyridamole Combination | 13 | |
| Overall Study | NOT COMPLETED | Brequinar Monotherapy | 1 | |
| Overall Study | NOT COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Brequinar-Dipyridamole Combination | 0 |
Source ClinicalTrials.gov
Adverse events30
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | Brequinar Monotherapy | 0 | 7 | |
| other | Headache | Nervous system disorders | Placebo | 1 | 6 | |
| other | Headache | Nervous system disorders | Brequinar-Dipyridamole Combination | 1 | 13 | |
| other | Vomiting | Gastrointestinal disorders | Brequinar Monotherapy | 1 | 7 | |
| other | Vomiting | Gastrointestinal disorders | Placebo | 0 | 6 | |
| other | Vomiting | Gastrointestinal disorders | Brequinar-Dipyridamole Combination | 2 | 13 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Brequinar Monotherapy | 0 | 7 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Placebo | 0 | 6 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Brequinar-Dipyridamole Combination | 1 | 13 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Brequinar Monotherapy | 0 | 7 |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Brequinar Monotherapy | 0 | 7 |
| Total, all-cause mortality | Placebo | 0 | 6 |
| Total, all-cause mortality | Brequinar-Dipyridamole Combination | 0 | 13 |
| Total, other adverse events | Brequinar Monotherapy | 1 | 7 |
| Total, other adverse events | Placebo | 3 | 6 |
| Total, other adverse events | Brequinar-Dipyridamole Combination | 3 | 13 |
| Total, serious adverse events | Brequinar Monotherapy | 0 | 7 |
| Total, serious adverse events | Placebo | 0 | 6 |
| Total, serious adverse events | Brequinar-Dipyridamole Combination | 0 | 13 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05166876
GET https://conductscience.org/api/trials/v1/NCT05166876/events?page=2